Schröck et al. suggested that SOX2 amplification is associated with poor prognosis of patients with HNSCC (including patients with advanced LN metastasis), and increases resistance to chemotherapy12. The gene discussed is SOX2; the disease is head and neck squamous cell carcinoma.